Chemexpress(SH:688131) Shang Hai Zheng Quan Bao·2025-07-29 17:44Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. has decided not to exercise the early redemption rights for its convertible bonds, "Haoyuan Convertible Bonds," despite meeting the conditions for redemption, to protect investor interests and demonstrate confidence in the company's long-term development and intrinsic value [2][12]. Group 1: Convertible Bond Issuance and Redemption - The company issued 8.2235 million convertible bonds with a total amount of 822.35 million yuan, with a maturity of 6 years [3]. - The bonds were listed on the Shanghai Stock Exchange on December 19, 2024, under the code "118051" [4]. - The initial conversion price was set at 40.73 yuan per share, later adjusted to 40.58 yuan and then to 40.59 yuan due to corporate actions [5][8]. Group 2: Redemption Conditions and Triggering Events - The redemption clause allows the company to redeem the bonds if the stock price exceeds 130% of the conversion price for at least 15 out of 30 consecutive trading days [9][11]. - From July 8 to July 29, 2025, the stock price met the redemption condition, triggering the right to redeem the bonds [11]. Group 3: Board Decision and Future Considerations - The board of directors convened on July 29, 2025, and unanimously decided not to exercise the early redemption rights for the bonds [12]. - The company will not exercise the redemption rights for the next three months, and if the redemption conditions are met again after October 30, 2025, the board will reassess the situation [12][17]. Group 4: Related Party Transactions - During the six months prior to the redemption condition being met, there were no transactions of the convertible bonds by major shareholders and executives, ensuring compliance with regulations [13][14]. Group 5: Compliance and Verification - The sponsoring institution confirmed that the decision not to redeem the bonds was approved by the board and complied with relevant regulations and guidelines [15][16].